CYANVAC
Cyanvac develops vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector. It is currently focused on developing robust, intranasal vaccines that are easy to administer, easy to transport, and easy to manufacture. Two of Cyanvac’s vaccine candidates are scheduled to enter clinical testing beginning in 2021, including an intrasal vaccine to serve as a booster for protecting against SARS-CoV-2 infection. The candidate was selected for the trial by an academic consortium that has run government-funded trials for other COVID-19 vaccines, and the clinical evaluation will be conducted at no cost to Cyanvac. Cyanvac also has vaccine candidates for the respiratory syncytial virus (RSV), norovirus, and Lyme Disease.
CYANVAC
Industry:
Biotechnology Health Care Manufacturing Medical Pharmaceutical
Founded:
2017-01-01
Address:
Athens, Georgia, United States
Country:
United States
Website Url:
http://www.cyanvacllc.com
Status:
Active
Contact:
(650) 518-9123
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Content Delivery Network Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Typekit
Current Employees Featured
Founder
Official Site Inspections
http://www.cyanvacllc.com Semrush global rank: 5.88 M Semrush visits lastest month: 1.41 K
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
